VectivBio Holding AG

The company's financials show resilient growth, with revenue advancing from $0.00 in Q2 2021 to $676000.00 in Q4 2022. Gross profit remained healthy with margins at 100% in Q4 2022 compared to N/A in Q2 2021. Operating income hit -$28.55M last quarter, sustaining a consistent -4224% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$28.64M. Net income dropped to -$28.48M, while earnings per share reached -$0.65. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.